The CRL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CRL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CRL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View CRL Detailed Price Forecast - CNN Money||View CRL Detailed Summary - Google Finance|
|View CRL Detailed Summary - Yahoo! Finance||View CRL Stock Research & Analysis - Zacks.com|
|View CRL Trends & Analysis - Trade-Ideas||View CRL Major Holders - Barrons|
|View CRL Call Transcripts - NASDAQ||View CRL Breaking News & Analysis - Seeking Alpha|
|View CRL Annual Report - CompanySpotlight.com||View CRL OTC Short Report - OTCShortReport.com|
|View CRL Fundamentals - TradeKing||View CRL SEC Filings - Bar Chart|
|View Historical Prices for CRL - The WSJ||View Performance/Total Return for CRL - Morningstar|
|View the Analyst Estimates for CRL - MarketWatch||View the Earnings History for CRL - CNBC|
|View the CRL Earnings - StockMarketWatch||View CRL Buy or Sell Recommendations - MacroAxis|
|View the CRL Bullish Patterns - American Bulls||View CRL Short Pain Metrics - ShortPainBot.com|
|View CRL Stock Mentions - StockTwits||View CRL Stock Mentions - PennyStockTweets|
|View CRL Stock Mentions - Twitter||View CRL Investment Forum News - Investor Hub|
|View CRL Stock Mentions - Yahoo! Message Board||View CRL Stock Mentions - Seeking Alpha|
|View Insider Transactions for CRL - SECform4.com||View Insider Transactions for CRL - Insider Cow|
|View CRL Major Holdings Summary - CNBC||View Insider Disclosure for CRL - OTC Markets|
|View Insider Transactions for CRL - Yahoo! Finance||View Institutional Holdings for CRL - NASDAQ|
|View CRL Stock Insight & Charts - FinViz.com||View CRL Investment Charts - StockCharts.com|
|View CRL Stock Overview & Charts - BarChart||View CRL User Generated Charts - Trading View|
Charles River Laboratories Awarded Five-Year, $95.7 Million Contract by the National Institute of Allergy and Infectious Diseases
Posted on Tuesday October 16, 2018
Charles River Laboratories International, Inc. (CRL) today announced that it was awarded a five-year, $95.7 million contract by the National Institute of Allergy and Infectious Diseases (NIAID), which is one of the largest institutes of the National Institutes of Health (NIH). Under NIAID’s Division of Intramural Research animal care program, Charles River will manage and provide staffing for NIAID’s on-site vivarium and related research model operations. The program is required to ensure the humane care and use of research models, and the efficient management of NIAID’s research model operations.
See what the IHS Markit Score report has to say about Charles River Laboratories International Inc.
Posted on Thursday October 11, 2018
Charles River Laboratories International Inc NYSE:CRL
Charles River Laboratories Schedules Third-Quarter 2018 Earnings Release and Conference Call
Posted on Wednesday October 10, 2018
Charles River Laboratories International, Inc. will release third-quarter 2018 financial results on Wednesday, November 7th, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, November 7th, at 8:30 a.m.
Cancer center CEO leaves Merck board after disclosure scandal
Posted on Tuesday October 02, 2018
The New York Times previously reported Thompson's resignation from Merck and from lab services company Charles River Laboratories International Inc. The move follows the resignation of Sloan Kettering's chief medical officer, Jose Baselga, in September, after a New York Times and Pro Publica investigation revealed that he had not disclosed millions of dollars in payments from health-care companies in many of his research articles.